Defence Therapeutics (OTCMKTS:DTCFF) Trading Down 23.5%

Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFFGet Rating) dropped 23.5% during mid-day trading on Thursday . The stock traded as low as $2.13 and last traded at $2.13. Approximately 350 shares were traded during trading, a decline of 3% from the average daily volume of 361 shares. The stock had previously closed at $2.79.

Defence Therapeutics Trading Down 23.5 %

The company’s 50-day simple moving average is $2.90 and its 200-day simple moving average is $2.84.

Defence Therapeutics Company Profile

(Get Rating)

Defence Therapeutics Inc, a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.

Read More

Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with's FREE daily email newsletter.